THERAPY DOSSIER · th-d2f93860c7d0

Rhizoma Coptidis and Coptis chinensis aqueous extract (RCE)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00704236 ↗PHASE4completed

Effect on insulin resistance of traditional Chinese treatment (Coptis chinensis, Astragalus membranaceus, Lonicera japonica) in type 2 diabetes

Type 2 Diabetes

Enrolment: 43 · Results not recorded

NCT00014378 ↗PHASE1completed

Phase I study of the Chinese herb Huanglian (Coptis chinensis) in patients with advanced solid tumours

Advanced Solid Tumor

Enrolment: 34 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23675786 ↗2013Reported benefit

The effect of RHIZOMA COPTIDIS and COPTIS CHINENSIS aqueous extract on radiation-induced skin injury in a rat model.

RatRadiationMale and femalen = 5 rats per group euthanised at each of 2 and 49 days after…

Model: Radiation-induced skin injury from a single 45 Gy dose of beta-ray irradiation

RCE reduced radiation-induced skin damage on histology, lowered serum and skin malondialdehyde (4.57 plus or minus 0.21 versus 5.54 plus or minus 0.21 mmol/ml in serum at 2 days) and limited the fall in superoxide dismutase activity.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…